Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005316 · ClinicalTrials.gov registry record
Alloantibodies in Pediatric Heart Transplantation
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- 290
- Enrollment target
NCT01005316 is a clinical trial that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 290 participants.
The verdict
NCT01005316 was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- 290 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the clinical outcomes of sensitized pediatric heart transplant recipients with a positive donor-specific cytotoxicity crossmatch and to compare this group with outcomes in nonsensitized heart transplant recipients.
Interventions
- DRUG Mycophenolate Mofetil
- DRUG Tacrolimus
- DRUG Induction Therapy
- PROCEDURE Intraoperative plasma exchange/pheresis
- PROCEDURE Short-term post-operative plasmapheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01005316
The ClinicalTrials.gov registry entry for NCT01005316 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Mycophenolate Mofetil is the first listed.
NCT01005316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01005316 about?
NCT01005316 is a clinical study titled "Alloantibodies in Pediatric Heart Transplantation". The purpose of this study is to determine the clinical outcomes of sensitized pediatric heart transplant recipients with a positive donor-specific cytotoxicity crossmatch and to compare this group with outcomes in nonsensitized heart transplant recipients.
What is the current status of trial NCT01005316?
This trial is currently terminated. The enrollment target is 290 participants. The study started on 2010-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01005316?
The interventions under investigation include: Mycophenolate Mofetil (DRUG), Tacrolimus (DRUG), Induction Therapy (DRUG), Intraoperative plasma exchange/pheresis (PROCEDURE), Short-term post-operative plasmapheresis (PROCEDURE).
Who is sponsoring clinical trial NCT01005316?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.